Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James McGovern

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Applied Crystallography|August 14, 2020
A new parafocusing paradigm for X-ray diffractionDanae Prokopiou, James McGovern, Gareth Davies, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2003
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancerTien Hoang, KyungMann Kim, Anthony Jaslowski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancerTien Hoang, KyungMann Kim, Joseph Merchant, et al.
Cancer Investigation|March 23, 2005
Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network StudyBrad S Kahl, Howard H Bailey, Eileen P Smith, et al.
Investigational New Drugs|October 28, 2003
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancerGlenn Liu, Kurt Oettel, Howard Bailey, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Applied Crystallography|August 14, 2020
A new parafocusing paradigm for X-ray diffractionDanae Prokopiou, James McGovern, Gareth Davies, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2003
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancerTien Hoang, KyungMann Kim, Anthony Jaslowski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancerTien Hoang, KyungMann Kim, Joseph Merchant, et al.
Cancer Investigation|March 23, 2005
Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network StudyBrad S Kahl, Howard H Bailey, Eileen P Smith, et al.
Investigational New Drugs|October 28, 2003
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancerGlenn Liu, Kurt Oettel, Howard Bailey, et al.
Pageof 1